Devices Oncology

 News Release - July 24, 2007

IntraOp Medical Corporation Delivers Mobetron to St. Vincent Indianapolis Hospital

Mobetron Delivers Intraoperative Electron Radiation Therapy to Patients as They Undergo Surgery--Safely and Quickly

SUNNYVALE, Calif.--(HSMN NewsFeed)--IntraOp Medical Corporation (OTCBB:IOPM ), a provider of innovative technology solutions for the treatment and eradication of cancer, today announced it has delivered Mobetron® to St. Vincent Indianapolis Hospital. A fully portable, self-shielded electron-beam radiation unit, Mobetron directly delivers intraoperative electron radiation therapy ("IOERT") to patients as they undergo surgery in a highly safe and efficient manner. Indianapolis is the first city to have more than one Mobetron; the solution is also currently available at Clarion Methodist Hospital.

St. Vincent Indianapolis Hospital is a major referral center for cancer care and other specialties throughout Indiana. Recently, it became one of 14 hospitals to be designated by the NCI as part of the NCI Community Cancer Center Program; this pilot program aims to deliver the most advanced cancer care to a greater number of Americans. The hospital reaches out to nearby communities through St. Vincent Health, the regional system of 16 hospitals of which it is a founding member. St. Vincent Health's service area spans over 45 urban, suburban, and rural counties in central Indiana, making it the state's largest hospital system. The 16 hospitals in the St. Vincent Health system saw a total of 2,897 new cancer patients in 2005.

Mobetron will be used at St. Vincent Indianapolis Hospital to safely and efficiently treat a wide variety of cancers. With Mobetron, radiation and surgical oncologists can pinpoint the exact area that requires radiation and immediately deliver high doses directly to the affected tissue during cancer surgery. Hospitals can wheel Mobetron between existing operating rooms without investing in costly renovations to accommodate traditional radiation therapy devices. Key patient benefits of this early and powerful start to radiation therapy include: better local tumor control, increased survival rates, shorter treatment cycles, and fewer side effects.

Donald A. Goer, president and CEO of IntraOp Medical Corporation said, "We are very pleased that St. Vincent Indianapolis Hospital has selected Mobetron as a core component of its cancer treatment program. This latest delivery demonstrates a continued interest and demand for IOERT solutions from leading cancer care facilities. We look forward to continuing to provide the most advanced tools doctors need to administer radiation therapy safely and effectively and, most importantly, to help save lives."

This is IntraOp's 21st delivery worldwide and the eighth in the United States. Other U.S. institutions using Mobetron include: University of California San Francisco, University of North Carolina, University Hospital Cleveland, Mayo Clinic Phoenix, Ohio State University, Clarion Methodist Hospital Indianapolis and University of Louisville.

For more information on St. Vincent Indianapolis Hospital, please visit: www.stvincent.org.

About IntraOp

IntraOp Medical Corporation provides innovative technology solutions for the treatment and eradication of cancer. Founded in 1993, IntraOp is committed to providing the tools doctors need to administer radiation therapy safely and effectively--for all cancer patients. The company's flagship product, Mobetron, is the first fully portable, self-shielding intraoperative electron radiation therapy device designed for use in any operating room. Key Mobetron benefits include: increased survival rates, better local tumor control, shorter treatment cycles, and fewer side effects. Leading hospitals, from university research centers to specialized cancer clinics in North America, Europe and Asia, use Mobetron as a vital part of their comprehensive cancer program.

For more information on IntraOp Medical Corporation, please visit www.intraopmedical.com.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the 1933 Securities Act and Section 21E of the 1934 Securities Exchange Act. Actual results could differ materially, as the result of such factors as competition in the markets for the company's products and services and the ability of the Company to execute its plans. By making these forward-looking statements, the Company can give no assurances that transactions described in this press release will be successfully completed, and undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Source: IntraOp Medical

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.